You are here

Article Text

Article menu

Download PDFPDF

Novel therapeutic targets
VEGF targeting by active immunisation improves joint inflammation and destruction in a murine model of rheumatoid arthritis
Free
  1. E Assier1,
  2. L Semerano1,2,
  3. L Delavallee1,
  4. D Damotte3,4,
  5. G Grouard-Vogel5,
  6. E Bernier5,
  7. D Zagury5,
  8. N Bessis1,
  9. M C Boissier1,2
  1. 1EA4222, Paris 13 University, Bobigny, France
  2. 2Department of Rheumatology, Avicenne Hospital, APHP, Bobigny, France
  3. 3UMRS872, CRC, Universities of Paris-Descartes and Pierre et Marie Curie, Paris, France
  4. 4Department of Pathology, Hôtel Dieu (APHP), Paris, France
  5. 5Néovacs, Paris, France

https://doi.org/10.1136/ard.2010.129635h

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Background

    Cytokines play a key role in the development of rheumatoid arthritis (RA), allowing hypertrophy of the pannus by neovascularisation, articular inflammation and destruction. We recently demonstrated in experimental models the efficacy of vaccination against cytokines, using a heterocomplex of keyhole limpet hemocyanin (KLH) and human tumour necrosis factor (TNF), called TNF kinoid (K). Vascular endothelial growth factor (VEGF) is a …

    View Full Text